Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer (PROTECT)

Clinical Trial ID NCT00779402

Rank	Title	Journal	Year	PubWeight™‹?›
1	Novel therapies for metastatic castrate-resistant prostate cancer.	J Natl Cancer Inst	2011	1.98
2	Trial watch: Dendritic cell-based interventions for cancer therapy.	Oncoimmunology	2012	1.51
3	Clinical opportunities and challenges in targeting tumour dormancy.	Nat Rev Clin Oncol	2012	1.26
4	Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions.	Clin Adv Hematol Oncol	2013	1.22
5	Emerging novel therapies in the treatment of castrate-resistant prostate cancer.	Can Urol Assoc J	2011	1.04
6	Prostate cancer vaccines: Update on clinical development.	Oncoimmunology	2013	0.98
7	Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.	Urology	2013	0.82
8	Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.	Ther Clin Risk Manag	2014	0.80
9	Immune response to sipuleucel-T in prostate cancer.	Cancers (Basel)	2012	0.79
10	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.	Oncoimmunology	2015	0.78
11	Immunotherapy for prostate cancer: False promises or true hope?	Cancer	2016	0.78